Alentis to Present Data at the EASL International Liver Congress 2021 for treatment of advanced liver fibrosis and prevention and treatment of hepatocellular carcinoma
Basel, June 23, 2021 – Alentis Therapeutics today announced that it will present data at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2021, being held virtually from June 23-26, 2021.
Data to be presented includes research from Alentis and academic collaborators that provides preclinical proof-of-concept in patient-derived cell-based and mouse models of CLDN1-specific mAbs for treatment of advanced liver fibrosis and prevention and treatment of hepatocellular carcinoma (HCC).
Presentations at the Digital International Liver Congress are listed below
Oral Presentation GS-2069: Claudin-1 is a target for treatment of advanced liver fibrosis and cancer prevention
Presenter: Natascha Roehlen, Inserm U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France; Université de Strasbourg, Strasbourg, France
Presentation Date and Time: June 24, 2021, 4:00 p.m. CEST
Oral Presentation OS-2190: A humanized Claudin-1 specific monoclonal antibody for treatment of hepatocellular carcinoma
Presenter: Natascha Roehlen, Inserm U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France; Université de Strasbourg, Strasbourg, France
Presentation Date and Time: June 25, 2021, 3:15 pm CEST
About Alentis Therapeutics
Alentis Therapeutics is a Swiss-based biotech that focuses on developing breakthrough treatments for fibrotic diseases. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).
The Company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need. Furthermore, the company uses a patient-derived drug and target discovery platform to develop medicines for advanced fibrosis.
Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.
Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.
For more information, visit https://alentis.ch/